Di-Dnp-L-LysineCAS# 1655-49-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1655-49-8 | SDF | Download SDF |
PubChem ID | 96818 | Appearance | Powder |
Formula | C18H18N6O10 | M.Wt | 478.4 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S)-2,6-bis(2,4-dinitroanilino)hexanoic acid | ||
SMILES | C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])NCCCCC(C(=O)O)NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-] | ||
Standard InChIKey | XFVSVNWYIWINEC-HNNXBMFYSA-N | ||
Standard InChI | InChI=1S/C18H18N6O10/c25-18(26)15(20-14-7-5-12(22(29)30)10-17(14)24(33)34)3-1-2-8-19-13-6-4-11(21(27)28)9-16(13)23(31)32/h4-7,9-10,15,19-20H,1-3,8H2,(H,25,26)/t15-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Di-Dnp-L-Lysine Dilution Calculator
Di-Dnp-L-Lysine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0903 mL | 10.4515 mL | 20.903 mL | 41.806 mL | 52.2575 mL |
5 mM | 0.4181 mL | 2.0903 mL | 4.1806 mL | 8.3612 mL | 10.4515 mL |
10 mM | 0.209 mL | 1.0452 mL | 2.0903 mL | 4.1806 mL | 5.2258 mL |
50 mM | 0.0418 mL | 0.209 mL | 0.4181 mL | 0.8361 mL | 1.0452 mL |
100 mM | 0.0209 mL | 0.1045 mL | 0.209 mL | 0.4181 mL | 0.5226 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 16-Hydroxy-2-oxocleroda-3,13-dien-15,16-olide
Catalog No.:BCN1536
CAS No.:165459-53-0
- bis[6-(5,6-dihydrochelerythrinyl)]amine
Catalog No.:BCN8232
CAS No.:165393-48-6
- SA 4503 dihydrochloride
Catalog No.:BCC6339
CAS No.:165377-44-6
- Hemiphroside B
Catalog No.:BCN1731
CAS No.:165338-28-3
- Hemiphroside A
Catalog No.:BCN1730
CAS No.:165338-27-2
- 1-Ethyl-3-nitrophthalate
Catalog No.:BCC8466
CAS No.:16533-45-2
- Cleroindicin E
Catalog No.:BCN1729
CAS No.:165197-71-7
- Shizukaol G
Catalog No.:BCN7879
CAS No.:165171-11-9
- Shizukaol E
Catalog No.:BCN7880
CAS No.:165171-09-5
- 6-Epidemethylesquirolin D
Catalog No.:BCN1728
CAS No.:165074-00-0
- Brevilin A
Catalog No.:BCN1727
CAS No.:16503-32-5
- Nα-Methylhistamine dihydrochloride
Catalog No.:BCC6701
CAS No.:16503-22-3
- DEPBT
Catalog No.:BCC2811
CAS No.:165534-43-0
- 12-O-tetradecanoylphorbol-13-acetate
Catalog No.:BCN2511
CAS No.:16561-29-8
- L-Stepholidine
Catalog No.:BCN2599
CAS No.:16562-13-3
- Methyl 6-acetoxyangolensate
Catalog No.:BCN1732
CAS No.:16566-88-4
- Torososide A
Catalog No.:BCN4694
CAS No.:165689-32-7
- Linezolid
Catalog No.:BCC2496
CAS No.:165800-03-3
- Eperezolid
Catalog No.:BCC5177
CAS No.:165800-04-4
- 1-Hydroxy-N-methylacridone
Catalog No.:BCN7551
CAS No.:16584-54-6
- Naltrexone
Catalog No.:BCC1783
CAS No.:16590-41-3
- Calystegine A5
Catalog No.:BCN1887
CAS No.:165905-26-0
- (-)-Tetramisole
Catalog No.:BCC4670
CAS No.:16595-80-5
- Z-Thr-OBzl
Catalog No.:BCC2737
CAS No.:16597-50-5
Antigenic modulation of the cytophilic binding of guinea-pig IgG and IgM antibodies to homologous macrophages.[Pubmed:86509]
Immunology. 1979 Apr;36(4):659-70.
The cytophilic binding of immune complexes by peritoneal exudate cells (PEC) from adjuvant-stimulated guinea-pigs was studied using 125I-labelled guinea-pig IgG1, IgG2 and IgM antibodies to the dinitrophenyl (DNP) group. The influence of hapten density upon cytophilic activity was studied by the addition of DNP-conjugated antigens to antibody in 2-200 molar ratios of DNP:antibody. Only IgG2 binding was enhanced by immune complex formation, and the increased binding of IgG2 anti-DNP was dependent on the number of DNP determinants per antigen molecule. Cytophilic activity with epsilon-DNP-L-lysine (DNP-LYS), alpha,epsilon-Di-Dnp-L-Lysine (DNP-LYS-DNP), or DNP1-8-BSA was no greater than that seen in the absence of hapten. Increased cytophilic binding was noted only with DNP20-41-BSA. The binding of IgG2 and IgG2 anti-DNP:DNP-bovine serum albumin (BSA) complexes was inhibited by monomeric IgG2. The relative cytophilic capacities of guinea-pig immunoglobulins appeared as follows: IgG greater than IgG1 greater than IgM. IgG1 and IgM binding of DNP conjugates did not enhance their cytophilic activity; therefore, IgG1 and IgM cytophilic binding to PEC was considered biologically insignificant. This investigation provides further evidence that cytophilic binding of immune complexes to macrophages is due to the co-operative action of multiple Fc sites rather than a conformational change in the IgG2 antibodies, and serum proteins, notably complement components, can alter the binding and/or phagocytosis of IgG2 anti-DNP:DNP-BSA complexes.